

Amendments to the Claims

Please amend claim 59 as indicated in the listing of claims.

Please cancel claims 2-22, 24-33, 55, 60 and 61 without prejudice or disclaimer.

Please add new claims 65-67 as presented below.

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Original) A substantially purified human small conductance calcium-activated channel-3 (hKCa3/KCNN3) polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.

Claims 2-58 (Canceled)

59. (Currently Amended) A composition ~~for administration of hKCa3/KCNN3 to a patient having an hKCa3/KCNN3-associated or hKCa3/KCNN3-related disorder~~ comprising:

- (a) a therapeutically effective amount of a substantially pure hKCa3/KCNN3 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2; and
- (b) a pharmaceutically acceptable carrier.

Claims 60-64 (Canceled)

65. (New) The composition of claim 59, wherein the carrier is a liposome.

66. (New) The composition of claim 59, wherein the polypeptide is conjugated to a carrier protein.

67. (New) The composition of claim 666, wherein the carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.